Secondary analysis of a Rotterdam treat-to-target trial (425 with RA): elderly-onset (>65 y, n=98) vs young-onset RA had similar DAS44 trajectories, less bDMARD initiation (28% vs 38%; HR 0.7, 95% CI 0.4 to 1) and similar AE-related treatment changes (43% vs 47%).
Secondary analysisn = 425
Dag et al. Treat-to-target strategies are feasible in elderly-onset rheumatoid arthritis given its reassuring risk-benefit profile